☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
CT-P39
Celltrion Reports Preliminary Results from the P-III Clinical Trial of CT-P39 (biosimilar, omalizumab) for Allergic Asthma and Chr...
April 10, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.